Rhumbline Advisers cut its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,663 shares of the biopharmaceutical company’s stock after selling 4,548 shares during the period. Rhumbline Advisers owned approximately 0.12% of Celldex Therapeutics worth $365,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Parametric Portfolio Associates LLC boosted its holdings in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after acquiring an additional 1,409 shares in the last quarter. Teachers Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 1,433 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after acquiring an additional 2,453 shares in the last quarter. American International Group Inc. boosted its holdings in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 3,880 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Celldex Therapeutics by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock valued at $1,943,000 after acquiring an additional 5,616 shares in the last quarter. Institutional investors and hedge funds own 56.69% of the company’s stock.

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, September 26th. ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $5.88.

Shares of Celldex Therapeutics, Inc. (NASDAQ CLDX) opened at 3.16 on Friday. The company’s 50-day moving average is $2.63 and its 200 day moving average is $2.78. The firm’s market capitalization is $405.56 million. Celldex Therapeutics, Inc. has a 1-year low of $2.20 and a 1-year high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The company had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $1.21 million. During the same quarter in the previous year, the company earned ($0.32) EPS. Celldex Therapeutics’s revenue was up 175.5% on a year-over-year basis. On average, analysts expect that Celldex Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/08/celldex-therapeutics-inc-cldx-stake-lessened-by-rhumbline-advisers.html.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.